Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Post-transplant malignancies in Taiwanese kidney transplant recipients: incidence, temporal trends, and immunosuppressive risk factors in a two-decade single-center cohort.

Created on 01 Sep 2026

Authors

Hsiang-Chen Hsieh, Jian-Ri Li, Shian Shiang Wang, Chuan-Shu Chen, Chun-Kuang Yang, Shun-Fa Yang

Published in

Frontiers in immunology. Volume 17. Pages 1738516. Epub Aug 17, 2026.

Abstract

Post-transplant malignancies (PTMs) remain major late immune-related complications after kidney transplantation, but long-term Asian data integrating immunologic exposures are limited.
We retrospectively analyzed 1,808 kidney transplant recipients from 2002 to 2022 at Taichung Veterans General Hospital, Taiwan. After exclusions, 1,734 patients were eligible. Outcomes included PTM incidence, spectrum, latency, temporal trends, and survival, with prespecified analyses of longitudinal tacrolimus trough levels and cumulative immunosuppressive burden.
PTM incidence was 11.7%. Urothelial (bladder 15.8%, upper tract 14.3%) and liver cancers predominated. One third occurred within 5 years with a median latency of 8.2 years. Bladder cancer declined after 2012 (26.7% vs. 11.2%, p = 0.010). Older age independently predicted PTM (HR 1.08 per year, p < 0.001) and mortality (HR 1.07 per year, p < 0.001). Higher long-term tacrolimus trough levels were independently associated with mortality in both the overall and PTM cohorts (HR 1.24 and 1.37, both p < 0.05). PTM patients had higher mortality (46.3% vs. 30.6%) with median post-diagnosis survival of 16.5 months.
PTMs in Taiwan are frequent and immunologically shaped, with a distinct urothelial and hepatic predominance and a post 2012 decline in bladder cancer plausibly linked to evolving immunosuppression, surveillance, and reduced carcinogen exposure. Older age and cumulative immunosuppressive burden were associated with PTM development, whereas higher long-term tacrolimus trough levels independently predicted mortality, underscoring the need for individualized immunosuppressive management and cancer type specific surveillance.

PMID:
42676682
Bibliographic data and abstract were imported from PubMed on 01 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 2
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement